Browse News
Filter News
Found 1,503 articles
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
Biologics Market Size to Hit Around USD 1. 37 Trillion By 2033
4/17/2024
According to the latest Research by Nova One Advisor, the global biologics market size was exhibited at USD 511.04 billion in 2024 and is projected to hit around USD 1,374.51 billion by 2033, growing at a CAGR of 10.4% during the forecast period 2024 to 2033.
-
Oncology Market Size to Exceed USD 521.60 Billion by 2033 | CAGR 8.9%
4/16/2024
The global oncology market size was valued at USD 222.36 billion in 2023 and is poised to grow from USD 242.15 billion in 2024
-
Looking for a biopharma job? Check out the BioSpace list of 11 top companies hiring life sciences professionals like you.
-
After an initial rejection due to safety issues, followed by a dispute and deferred actions, Akebia Therapeutics on Wednesday finally won the FDA’s nod for vadadustat as a treatment for anemia caused by chronic kidney disease.
-
Pharmaceutical Market Size to Hit Around USD 2,832.66 Bn by 2033
3/28/2024
According to Vision Research Reports, the global pharmaceutical market size was estimated at USD 1,559.53 billion in 2023 and it is expected to surpass around USD 2,832.66 billion by 2033.
-
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
3/28/2024
Akebia Therapeutics®, Inc. announced that the U.S. Food and Drug Administration has approved Vafseo® Tablets for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months.
-
Vafseo® approved by the U.S. FDA for the treatment of anemia due to chronic kidney disease in dialysis-dependent adult patients
3/28/2024
CSL Vifor is pleased that its partner Akebia Therapeutics, Inc. announced that the U.S. Food and Drug Administration has approved Vafseo tablets for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months.
-
Deep Dive: Drug Price Reform
3/20/2024
In this deep dive, BioSpace takes a closer look at the drug price crisis in the U.S. As President Joe Biden and former President Donald Trump gear up for a rematch in the 2024 election, we explore how federal reforms to lower costs could be leveraged on the campaign trail.
-
U.S. Pharmacy Benefit Management Industry is Rising Rapidly
3/19/2024
The U.S. pharmacy benefit management market size is anticipated to surpass around USD 861.5 billion by 2030 with a CAGR of 9.05% over the forecast period 2022 to 2030.
-
Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
3/19/2024
CSL Vifor announced that Health Canada has authorized Ferinject for the intravenous treatment of iron deficiency anemia in adult and pediatric patients one year of age and older when oral iron preparations are not tolerated or are ineffective, as well as for the treatment of iron deficiency in adult patients with heart failure and New York Heart Association class II/III* to improve exercise capacity.
-
List Biotherapeutics and Sacco System Announce Lead Share Agreement
3/14/2024
List Biotherapeutics, Inc. and Sacco System Australia Pty Ltd announced a lead share agreement to introduce and mutually recommend each other's microbial development and manufacturing services to prospective customers if one party discovers a project that is better suited to the other party's capability or capacity.
-
Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)
3/11/2024
Travere Therapeutics, Inc. announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration for conversion of the existing U.S. accelerated approval of FILSPARI® in IgA nephropathy to full approval.
-
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress
3/7/2024
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT) today announced its financial results for the fourth quarter ended December 31, 2023, and provided corporate updates.
-
Despite the changing landscape in biopharma, many companies are still recruiting. If you’re looking to make a career change, here are 12 biopharma companies hiring on BioSpace now.
-
Kamada Issues 2024 CEO Letter to Shareholders
3/6/2024
Kamada Ltd., a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, issued a Letter to Shareholders from Amir London, Chief Executive Officer.
-
CSL Seqirus is Fully Prepared to Implement the FDA's Vaccines and Related Biological Products Advisory Committee Trivalent Influenza Vaccines Strain Selection for the 2024/25 U.S. Season
3/6/2024
CSL Seqirus, a global leader in the protection of public health, confirmed it is fully prepared to deliver its influenza vaccine portfolio for the 2024/25 U.S. season, based on the trivalent strains recommended this week by the U.S. Food and Drug Administration's Vaccines and Related Biological Products Advisory Committee.
-
Genezen Announces Strategic Process Development and Manufacturing Partnership Agreement with Seattle Children's Research Institute for X-linked Agammaglobulinemia (XLA) Cell Therapy Program
3/6/2024
Seattle Children's Research Institute, the research division of Seattle Children's Hospital and renowned global leader in pediatric research, and Genezen, a leading gene and cell therapy contract development and manufacturing organization, have unveiled a strategic manufacturing partnership for Seattle Children's Research Institute's X-linked agammaglobulinemia program.
-
Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
3/4/2024
Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the fourth quarter and full year ended December 31, 2023.
-
uniQure Announces 2023 Financial Results and Highlights Recent Company Progress
2/28/2024
uniQure N.V. reported its financial results for the fourth quarter and full year 2023 and highlighted recent progress across its business.